



Interchina Commercial Building, 1112A

No 33. Deng Shi Kou Street

Dong Cheng, Beijing

Phone: (010) 6528-0877

Fax: (010) 6528-0834

北京市东城区灯市口大街 33 号

国中商业大厦 1112A 室, 100006

电话: (010) 6528-0877

传真: (010) 6528-0834

china@edanzwriting.com

## **Edanz Journal Selection Tool**

### **How to use the journal selection tool:**

- 1. Consider the focus of your paper, its strengths and weaknesses, the significance of its findings and the broadness of its appeal.**
- 2. Review the important factors to consider when selecting a journal in light of the above considerations (pg. 2)**
- 3. Search and browse relevant literature databases, publisher websites and your own reference list to find candidate target journals. Add the titles of any candidate journals to the boxes in the left column of the Journal Selection Matrix (pg. 3).**
- 4. Go to the websites of your selected candidate journals, immediately crossing off any that don't meet your requirements or for which your study would be deemed inappropriate (based on steps 1 and 2 above).**
- 5. Fill in the relevant data for each remaining candidate journal using the other columns of the Journal Selection Matrix to enable you to make an informed decision. The sample journal selection report (pg. 4–6) shows the sorts of information that can be obtained from journal websites.**
- 6. Prepare your cover letter to the editor of the selected journal and submit your manuscript and cover letter together.**

## Important factors to consider when choosing a journal

**Publishing frequency:** This is the number of times the journal is published each year. More frequent publishing usually means the Journal can publish more manuscripts each year. This may also affect the anticipated time to publication once the manuscript is accepted.

**Publication type:** This indicates whether the journal is published in print form only (the Journal is only posted to subscribers), online only (issues are available online to subscribers or to those who buy access to a specific manuscript) or both (the Journal is available both in print and online).

**Open Access:** Many journals also offer Open Access online. This means that the Journal (or specific manuscripts) can be read by anyone, not just subscribers. However, Journals often charge a fee for Open Access, which is charged to the Author.

**Impact Factor:** This is simply the Impact Factor cited by the Journal, as prepared for the Journal Citation Report. However, not all Journals state this information.

**Target audience:** This section provides a summary of who is likely to read that Journal. Where available, we will also indicate the number of subscribers to that journal.

**Aims and scope:** This section provides a summary of the Aims and Scope of the Journal, including the subject areas and types of manuscripts published (e.g., Letters to the Editor, Short/Brief Communications, full articles).

**Rejection rate:** Where possible, we will state how many of the manuscripts submitted to the Journal are rejected. However, not all Journals state this information.

**Lead times:** Where possible, we will state how long (1) peer review takes and (2) how quickly the manuscript is published on acceptance. Shorter lead times mean your manuscript will be reviewed and published quicker (if accepted). Some journals offer 'rapid pre-publication' of accepted manuscripts, which are unformatted and non-final versions.

**Prior publications:** Here, we provide a list of related studies that have been published in the Journal. Some studies are identified based on the literature cited in your manuscript, others are identified using selected keywords.

**Publication fee:** Some journals charge a fee for publishing the manuscripts, which may be *per printed page* or *per article*. This fee may be listed to either defray the costs of publication, as an Open Access fee, or as a Article Processing Charge. Some journals also offer a Fast Track fee option, to speed up the submission and publication processes.

### Journal Selection Matrix

Journal	Publishing frequency; type; Impact factor	Target audience	Aims and scope	Prior publications relevant to your manuscript

**Sample Journal Recommendation (part of Edanz's Focus Services for manuscript acceptance)**

Journal	Publishing frequency; type; Impact factor	Target audience	Aims and scope	Prior publications relevant to your manuscript
<p><i>Cancer Gene Therapy</i></p> <p><i>Cancer Gene Ther</i></p> <p>Editors: RE Sobol, KJ Scanlon</p>	<p>Monthly (12 issues per year)</p> <p>Online and in print</p> <p>Impact factor: 3.889 (2007)</p>	<p>Cancer researchers and clinicians</p>	<p><i>Cancer Gene Therapy</i> is the essential gene therapy resource for cancer researchers and clinicians, keeping readers up to date with the latest developments in gene therapy for cancer. It publishes original laboratory and clinical research papers, case reports and review articles on topics including RNAi approaches, drug resistance, hematopoietic gene transfer, homologous recombination, ribozyme technology, antisense technology, tumor immunotherapy and tumor suppressors, translational research, cancer therapy, gene delivery systems (viral and non-viral), anti-gene therapy (antisense, siRNA &amp; ribozymes), apoptosis; mechanisms and therapies, vaccine development, immunology and immunotherapy, DNA synthesis and repair</p>	<p>O, Blaszczyk-Thurin, Shen et al. A DNA vaccine expressing tyrosinase-related protein-2 induces T-cell-mediated protection against mouse glioblastoma. <i>Cancer Gene Ther</i> 2003; 10: 678–88.</p> <p>O-Sullivan, Chopra, Kim et al. New strategy for the identification of squamous carcinoma antigens that induce therapeutic immune responses in tumor-bearing mice. <i>Cancer Gene Ther</i> 2007; 14: 389–398.</p> <p>Victoria, Socorro-Silva, Volsi et al. Immune response to vaccination with DNA-hsp65 in a phase I clinical trial with head and neck cancer patients. <i>Cancer Gene Ther</i> 2009; doi: 10.1038/cgt.2009.9</p>
<p><i>Molecular Cancer Therapeutics</i></p> <p><i>Mol Cancer Ther</i></p> <p>Editor-in-Chief: Daniel D. Von Hoff</p>	<p>Monthly (12 issues per year)</p> <p>Online and in print</p> <p>Impact factor not reported (current volume: 8)</p>	<p>Clinicians and Researchers involved in developing molecular therapies for cancer</p>	<p><i>Molecular Cancer Therapeutics</i> focuses on basic research that has implications for cancer therapeutics in the following areas: Experimental Cancer Therapeutics, Identification of Molecular Targets, Targets for Chemoprevention, New Models, Cancer Chemistry and Drug Discovery, Molecular and Cellular Pharmacology, Molecular Classification of Tumors, and Bioinformatics and Computational Molecular Biology. The journal provides a publication forum for these emerging disciplines that is focused specifically on cancer research. Papers are stringently reviewed and only those that report results of novel, timely, and significant research and meet high standards of scientific merit will be accepted for publication.</p>	<p>Huebener, Fest, Strandsby et al. A rationally designed tyrosine hydroxylase DNA vaccine induces specific antineuroblastoma immunity. <i>Mol Cancer Ther</i> 2008; 7: 2241–51.</p> <p>Li, Bharadway, Zhang et al. Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. <i>Mol Cancer Ther</i> 2008; 7: 286–96.</p> <p>Hoffmann, Bayer, Grunwalk et al. Intratumoral expression of respiratory syncytial virus fusion protein in combination with cytokines encoded by adenoviral vectors as in situ tumor vaccine for colorectal cancer. <i>Mol Cancer Ther</i> 2007; 6: 1942-50.</p>

Journal	Publishing frequency; type; Impact factor	Target audience	Aims and scope	Prior publications relevant to your manuscript
<p><i>Human Gene Therapy</i></p> <p><i>Hum Gene Ther</i></p> <p>Editor-in-Chief: James M Wilson</p>	<p>Monthly (12 issues per year)</p> <p>Online and in print</p> <p>Impact factor: 4.330 (2008)</p>	<p>Clinicians and researchers allied to gene therapy</p>	<p><i>Human Gene Therapy</i> is the definitive peer-reviewed rapid-publication journal covering all aspects of human gene therapy. The Journal publishes scientific papers on original investigations into the transfer and expression of genes in mammals, including humans. Improvements in vector development, delivery systems, and animal models, particularly in the areas of cancer, heart disease, viral disease, genetic disease, and neurological disease, are covered.</p> <p>Other key features include a continuously updated directory of human gene marker and gene therapy clinical protocols, as well as ethical/legal/regulatory papers related directly to the area of gene transfer into humans.</p>	<p>Facciabene, Aurisicchio, Elia et al. DNA and adenoviral vectors encoding carcinoembryonic antigen fused to immunoenhancing sequences augment antigen-specific immune response and confer tumor protection. <i>Hum Gene Ther</i> 2006; 17(1): 81–92.</p> <p>Cheng, Hung, Hsu et al. Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion. <i>Hum Gene Ther</i> 2002; 13(4): 553–68.</p>

Journal	Publishing frequency; type; Impact factor	Target audience	Aims and scope	Prior publications relevant to your manuscript
<p><i>Genetic Vaccines and Therapy</i></p> <p><i>Genet Vaccines Ther</i></p> <p>Editor-in-Chief: Shyam S. Mohapatra</p>	<p>Published online</p> <p>Articles published on acceptance</p> <p>Article processing charge: £925, US\$1325 €990</p>	<p>Researchers, clinicians and biotechnologists in the field of gene-based therapy and drug delivery</p>	<p>Genetic Vaccines and Therapy is an Open Access, peer-reviewed, online journal dedicated to applying new knowledge about genetics in treating human disease</p> <p>Genetic Vaccines and Therapy is aimed at researchers, clinicians and biotechnologists, worldwide, in the field of gene-based therapy and drug delivery. Examples of current topics of interest include: development of new biocompatible delivery materials, design of effective and safe vectors, exploration of new strategies for targeting drugs, and application of siRNA gene silencing to specific disease therapies. The field of genetic therapy is just beginning to see an increase in interest and applicability in the pharmaceutical and biotechnology community, and the editors have positioned this journal to meet the needs of workers in this new and highly promising area.</p> <p>The goal of this new journal was to provide a platform for materials scientists and gene-delivery specialists, to come together with researchers and clinicians to explore new ways of combating disease by using DNA-based therapeutic agents. Traditional gene therapy has been aimed primarily at correcting hereditary problems; the focus of this journal is broader, including the use of gene expression vectors for the endogenous production of factors designed to interfere with a wide range of diseases, including: asthma, viral infection, cancer and Alzheimer's disease.</p>	<p>Lai, Yen, Lin et al. The effects of DNA formulation and administration route on cancer therapeutic efficacy with xenogenic EGFR DNA vaccine in a lung cancer animal model. <i>Genet Vaccines Ther</i> 2009; 7:2</p> <p>Hao, Xiu, Zehua et al. Genetic immunization with hantavirus vaccine combining expression of G2 glycoprotein and fused interleukin-2. <i>Genet Vaccines Ther</i> 2008; 6:15</p>

## More about Edanz's Journal Selection Service

Publishing in a high impact factor journal is important for your career and helps you secure more funding for your research. We use our knowledge to generate a short-list of journals (three or five, depending on your choice) that we believe will be most appropriate and most likely to consider your work. We also give an assessment of the benefits and risks of submitting to each journal to enable you to make the most appropriate decision of your target journal. Edanz Writing can recommend a journal to meet your publication needs. We consider the following when identifying potential target journals:

Recent publication history

Scope of your study

Type of study (e.g., clinical study, case study, laboratory study)

Type of manuscript (e.g., short communication, full article, review article, letter to the editor)

Do you need to publish in a journal with an Impact Factor/indexed in Medline/Embase, etc.?

Note that journal selection reports, such as the sample one included above, are returned with a detailed cover letter explaining the different advantages of each candidate journal, suggesting first and second choices of target journal, and describing the rationale for the selections and ranking.

[Visit our website to find out more about Journal Selection and other Focus Services that will help you increase your chances of acceptance for publication: http://www.liwenbianji.cn/focus\\_services](http://www.liwenbianji.cn/focus_services)